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6/j.bThe success of treatment for sclerodermatous chronic graft-versus-host disease (ScGVHD) remains disap-
pointing. The immunomodulatory ability of bone marrow (BM)–derived mesenchymal stem cells (MSCs)
shows promise in treating GVHD, especially given its previous success in treating patients with acute
GVHD (aGVHD). The potential efficacy and safety issues for treating cGVHD, particularly ScGVHD, remain
to be clarified, however. Here, we report 4 patients with ScGVHD who received MSCs expanded ex vivo
from unrelated donors by intra-BM injection. After MSC infusion, the ratio of helper T lymphocyte (Th) 1
cells to Th2 cells was dramatically reversed, with an increase in Th1 and a decrease in Th2 achieving
a new balance. Correspondingly, symptoms gradually improved in all 4 patients. During the course of
MSC treatment, the patients’ vital signs and laboratory results remained normal. At the time of this report,
none of the 4 patients had experienced recurrence of leukemia. Although this study alone cannot guarantee
the application of MSCs in ScGVHD, our findings strongly suggest that this treatment is therapeutically prac-
ticable, with no detectable side effects. This approach may provide new insight into the clinical treatment of
ScGVHD, with the aim of greatly increasing the survival rate in patients with leukemia who undergo alloge-
neic BM transplantation (BMT).
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bmt.2009.11.006occurring in 25%-40% of patients who survive for
more than 100 days after AHCT [1]. The immunopa-
thogenesis of cGVHD is mediated in part by helper T
lymphocyte 2 (Th2) cells, with a syndrome of immuno-
deficiency and an autoimmune disorder [2,3]. cGVHD
affects almost all organs and tissues, manifested by
a marked increase in collagen deposition and a lack of
T lymphocyte infiltration in the target organ tissues.
The appearance of sclerotic skin lesions is the most
commonpathological change inpatientswith cGVHD;
this condition is termed sclerodermatous cGVHD
(ScGVHD). The main clinical manifestations of
ScGVHD include lichenoid lesions, sclerodermatous
lesions, disorders of pigmentation (eg, areasof hypopig-
mentation and hyperpigmentation), and leopard-skin
eruptions (widespread, well-delimited, hyperpigmen-
tated macules) [4-6].
Despite the widely used combination treatment of
steroids and cyclosporine A(CsA) or tacrolimus, the
outcome in patients with extensive ScGVHD remains
unsatisfactory. Other agents that have been studied in-
clude etritrenate, thalidomide, hydroxychloroquine,
extracorporeal photopheresis, ultraviolet (UV) B light,
and psoralen 1 UVA light [7], but these agents have403
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404 Biol Blood Marrow Transplant 16:403-412, 2010H. Zhou et al.been found to carry serious side effects. In addition, in-
fliximab, a humanized chimeric antibody against tu-
mor necrosis factor (TNF); etanercept, a TNF
antagonist [8]; and rituximab, an anti-CD20 chimeric
monoclonal antibody (mAb) [9,10] have been used to
treat cGVHD. Further study of this innovative ap-
proach is underway with the efficacy in the air. There
remains no effective, specific therapy to block the de-
velopment of cGVHD. ScGVHD, the most severe
form of the disease, is frequently refractory to standard
treatment modalities, further limiting therapeutic op-
tions for affected patients [11-13].
Numerous studies have shown that bone marrow
(BM)–derived mesenchymal stem cells (MSCs) have
profound immunomodulatory functions both in vitro
and in vivo. MSCs are known to modulate the prolifer-
ation, activation, and maturation of T and B lympho-
cytes in vitro in a dose-dependent and time-limited
manner [14,15]. Our laboratory first reported the im-
munomodulatory effects of MSCs on the abnormal
immune system of BXSB mice that were born with
an immunologic deficiency and developed lupus natu-
rally. The results showed that MSCs can significantly
down-regulate Th2 cells in pathological conditions
and further inhibit the abnormal activation of humoral
immunity to maintain the original balance. Further-
more, the renal function of BXSB mice exhibited
significant and lasting improvement [16]. MSCs also
can suppress the differentiation from Th0 cells to
Th1 cells and further affect cytoimmunity, making
this approach effective in treating acute GVHD
(aGVHD) [17-20]. But is MSC therapy effective in
patients with ScGVHD? To explore this question,
we treated 4 patients with ScGVHD with intra-BM
injection (IBMI) of MSCs.T
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PATIENTS AND METHODS
Patients
The study group comprised 4 patients with
ScGVHD (3 males, 1 female; median age, 41 years;
range, 38 to 43 years) presenting at the Affiliated
Hospital of Academy of Military Medicine Science
between September 2006 and August 2008. Informed
consent was obtained according to institutional guide-
lines in accordance with the Declaration of Helsinki.
The clinical protocol was approved by the institution’s
Ethics Committee. Baseline patient characteristics are
summarized inTable 1. aGVHDand cGVHDgrading
was performed according to classical criteria. All 4 pa-
tients underwent nonmyeloablative (NMA) AHCT for
a primary hematologic malignancy and developed
ScGVHD at a median time of 11.5 months (range,
4-19months) after transplantation. One of the patients
had a chest skin biopsy, the pathology report of which
supported the diagnosis of ScGVHD (Figure 1). All
Figure 1. Biopsy specimen of chest skin in patient 2 before MSC infu-
sion. Stratified squamous epithelium showing mild hyperkeratosis with
parakeratosis, basal cell liquefaction degeneration, and T lymphocytes
infiltrating into the superficial layer of the derma, with visible manipulus
of tissue cell–phagocytized hemosiderin. (Hematoxylin and eosin stain-
ing; original magnification 100.)
Biol Blood Marrow Transplant 16:403-412, 2010 405MSCs Alleviate ScGVHDpatients received standard immunosuppressant medi-
cations for ScGVHD, such as cyclosporine A(CsA),
thalidomide, prednisone, and tacrolimus, at a median
time of 17.3 months (range, 4.5-37.3 months) before
MSC treatment, but the condition did not improve.Ex Vivo MSC Culture Expansion
MSCs were collected from unrelated donors in
accordance with informed consent principles and
cultured as described previously [21,22]. In brief,
donor BM aspirates were collected, and mononuclear
cells (MNCs) were fractionated over a 1.077-g/mL Fi-
coll-Paque density gradient. The interface was col-
lected and resuspended in Dulbecco’s modified
Eagle’s medium (low-glucose DMEM/F12) and 40%
MCDB-201 medium (Sigma-Aldrich, St Louis, MO),
supplemented with 2% fetal bovine serum (FBS;
Gibco Life Technologies, Paisley, UK), 1-insulin
transferring selenium (Gibco Life Technologies),
1029 M dexamethasone (Sigma-Aldrich), 1024 M
ascorbic acid 2-phosphate (Sigma-Aldrich), 10 ng/
mL of epidermal growth factor (Sigma-Aldrich), and
10 ng/mL of platelet-derived growth factor BB
(Sigma-Aldrich), and then plated in culture flasks
(1  106 cells/mL). The culture was maintained at
37C in a humidified environment containing 5%
CO2. After 24-48 hours of culture, nonadherent cells
were removed, and the adherent layer was cultured
until it reached 70%-80% confluence. Cells were
then detached with 0.05% trypsin and 0.01% EDTA
and replated. MSCs were harvested and used at pas-
sages 3-6. All cell culture steps were performed in
the in-house Good Manufacturing Practices facility.Cell Surface Antigen Analysis
For immunophenotyping analysis, the expanded
cells were washed with phosphate-buffered saline(PBS) containing 0.5% bovine serum albumin (BSA;
Sigma-Aldrich), and incubated with primary antibodies
for 30 minutes at 4C. To detect intracellular antigens,
cells were fixed in 2%paraformaldehyde for 15minutes
at 4C, and then permeabilized with 0.1% saponin
(Sigma-Aldrich) for 1 hour at room temperature. The
working concentration for primary antibodies against
human Flk-1 (Santa Cruz Biotechnologies, Santa
Cruz, CA), CD29, CD31, CD34, CD44, CD45,
CD105, CD106, and HLA-DR (all from BD Biosci-
ences, San Diego, CA) was 20 ng/mL. Same-species,
same-isotype irrelevant antibodies were used as nega-
tive controls. Cells were incubated with fluorescein iso-
thiocyanate–conjugated secondary antibodies for 30
minutes at 4C after being washed with PBS containing
0.5% BSA. After another 3 washes, cells were resus-
pended in PBS and analyzed with a fluorescence-acti-
vated cell sorter (FACS; Vantage SE; BD Biosciences).
Multilineage Differentiation of MSCs
To identify the capacity for MSCmultilineage dif-
ferentiation, MSCs were cultured under differentia-
tion conditions. For adipocyte differentiation, MSCs
were cultured at 2-3  104/cm2 in DMEM with 10%
FCS, 1026 M dexamethasone, 50 mg/mL of ascorbic
acid, and 100 mg/mL of 1-methyl-3-isobutyl-xanthine
(all from Sigma-Adrich). After 14 days, Oil Red
O staining was performed to show adipocyte
differentiation.
For osteoblast differentiation, MSCs were cul-
tured at 1  104/cm2 in DMEM with 10% FBS, 10
mM b-glycerophosphate, 1027 M dexamethasone,
and 0.2 mM ascorbic acid (all from Sigma-Aldrich).
After 21 days, the cells were stained with von Kossa’s
stain to reveal osteogenic differentiation.
For chondrocyte differentiation, spheroids of
2  105 MSCs were formed by centrifugation at
800 rpm in 15-mL centrifuge tubes. After incubation
at 37C and 5% CO2 in chondrogenic induction me-
dium (DMEM supplemented with 2% FCS, 10 ng/
mL transforming growth factor b1, and 50 nM as-
corbic acid [all from Sigma]) for 4 days, the spher-
oids were transferred to 96-well U-bottomed
plates. After 21 days, the spheroids were harvested
and fixed in 10% buffered formalin for 2 hours at
room temperature. The fixed spheroids were then
dehydrated by treatment with a series of graded al-
cohols, cleared by treatment with xylene, and infil-
trated with paraffin. Paraffin sections (8 mm) were
stained with 0.1% Safranin O to detect mucopoly-
saccharide synthesis.
Mitogen Proliferative Assays
In the mitogen proliferative assays, triplicate wells
containing responder 1  105 MNCs were cultured
with 50 mg/mL of phytohemagglutinin (PHA; Roche,
Table 2. Summary of MSC Infusion
Patient Frequency
Inversion
Time, Day
Dose,
Cells/2 mL
Concomitant
Medications, mg/Day
1 1 0 1.2  107 PDN(20)-TAC(19)
-TDM(50)
2 +9 2.0  107
3 +14 1.0  107
4 +22 2.0  107
5 +28 2.0  107
6 +35 2.0  107
7 +49 2.0  107
8 +52 1.5  107
2 1 0 1.0  107 PDN(5)
2 +14 2.1  107
3 +39 1.1  107
4 +47 1.0  107
3 1 0 1.8  107 TAC(19)
2 +8 1.5  107
3 +15 1.0  107
4 +22 2.0  107
4 1 0 2.2  107 PDN(5)-MMF(0.25)
2 +7 1.7  107
3 +14 1.4  107
4 +28 2.1  107
5 +38 2.0  107
6 +45 1.9  107
7 +52 1.0  107
MSC indicates mesenchymal stem cells; TAC, tacrolimus; TDM, thalido-
mide; PDN, prednisone.
406 Biol Blood Marrow Transplant 16:403-412, 2010H. Zhou et al.Mannheim, Germany) in a total medium volume of 0.1
ml at 37C in 5% CO2, and MSCs were added on day
0. Irradiated MSCs (30 Gy) were cocultured with the
MNCs at a MSC: MNC ratio of 1:10. Control wells
contained only MNCs. Cultures were pulsed with 1
mCi/well of tritiated thymidine (Shanghai Nucleus Re-
search Institute, China) on day 2, and harvested 18
hours later with a Tomtec automated harvester (Wal-
lac, Gaithersburg, MD). Thymidine uptake was quan-
tified using a liquid scintillation and luminescence
counter (TRILUX; Wallac).
MSC Infusion and Therapeutic Effect Evaluation
The patients received MSC infusion at a dose of
1.0-2.0  107 cells by IBMI from the anterosuperior
iliac spine. MSCs from the same donor for the same
patient were infused more than once. Because of dif-
ferences in the patients’ condition, family circum-
stances, and hospital and other factors, the number
of infusions ranged from 4 to 8. Concomitant medi-
cations for ScGVHD were individualized for each
patient, but all were current standard medicines,
and the doses were tapered significantly (Table 2).
The physical examination included skin scoring and
range-of-motion assessment. The modified Rodnan
skin (RS) score was used to assess cutaneous sclerosis
changes [23]. The RS scale grades skin thickness
from 0 to 3 as follows: 0, uninvolved skin; 1, skin in-
volved with ability to pinch; 2, inability to pinch; 3,
inability to move. The pinch is done in a single
movement of moderate intensity, using only the fin-
gertips. All affected areas were assessed, and the re-
sults of all areas were added to give a final overall
score.
Immunofluorescent Staining of Intracellular
Cytokines and Flow Cytometric Analysis
Stimulation of Peripheral Blood Mononuclear
Cells (PBMCs)
MNCs were prepared from patients’ peripheral
blood (PB) by Ficoll-Paque density gradient centri-
fugation and suspended in RPMI 1640 medium sup-
plemented with 10% (vol/vol) FCS, 2 mM
l-glutamine, 0.1 mM nonessential amino acids (Life
Technologies, Carlsbad, CA), 1 mM sodium pyru-
vate, 100 U/mL penicillin, 100 mg/mL streptomycin,
1% HEPES buffer, and 10 mM 2-mercaptoethanol.
To stimulate interleukin (IL)-2 and interferon
(IFN)-g production, PBMCs were stimulated for 6
hours with 5 ng/mL phorbol myristate acetate
(PMA; Sigma-Aldrich) and 500 ng/mL ionomycin
(Sigma-Aldrich) in the presence of a protein trans-
port inhibitor containing monensin (GolgiStop;
Sigma-Aldrich). To stimulate IL-10 production,
PBMCs were stimulated for 24 hours with 1.0 mg/
mL of lipopolysaccharide (LPS; Sigma-Aldrich) inthe presence of GolgiStop. For stimulating IL-4 pro-
duction, PBMCs were stimulated for 2 days with 50
mg/mL of PHA (Roche), washed, and then cultured
in medium containing 10 ng/mL of rhIL-2 and 20
ng/mL of rhIL-4 (both from Sigma-Aldrich) for 3
days. Finally, the cells were harvested and restimu-
lated for 4 hours with PMA and ionomycin in the
presence of GolgiStop.
Immunofluorescent Staining of Intracellular
Cytokines and Flow Cytometric Analysis
The stimulated cells were washed with PBS con-
taining 0.5% BSA (Sigma-Aldrich), fixed in 2% para-
formaldehyde for 15 minutes at 4C, permeabilized
with 0.1% saponin (Sigma-Aldrich) for 1 hour at
room temperature, and then incubated with phycoery-
thrin (PE)-conjugated primary antibodies for 30 min-
utes at 4C. The working concentration for primary
antibodies against human IL-2, IFN- g, IL-10, and
IL-4 (BD Biosciences) was 20 ng/mL. Same-species,
same-isotype irrelevant antibodies were used as nega-
tive controls. After 3 washes, cells were resuspended
in PBS and analyzed using a Vantage SE FACS (BD
Biosciences).
Statistics
All statistical analyses were performed using SPSS
version 13.0 (SPSS Inc, Chicago IL). The paired-sam-
ple t-test was used to test the probability of significant
differences between samples. Statistical significance
was defined as P\ .05.
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Characteristics of MSCs
Morphology and Phenotype Analysis
MSCs from donor BM gave rise to a population of
adherent cells characterized by the presence of a pre-
dominant cell type with a typical fibroblast-like
morphology (Figure 2A). MSCs could be ex vivo ex-
panded by successive cycles of trypsinization, seeding,
and culture. The phenotype of MSCs was Flk1-,
CD29-, CD44-, CD106-, and CD105-positive, and
CD34-, CD31-, and HLA-DR– negative (Figure 2E),
in accordance with our previous findings.
Adipogenic Differentiation
When MSCs were cultured in adipogenic medium
for 2 weeks, more than 80%-90% of cells differenti-
ated into lipid-laden cells that were stained by Oil
Red O (Figure 2B).
Osteogenic Differentiation
When MSCs were cultured in osteogenic medium
for 3 weeks, more than 80% of cells could be induced
into osteogenic lineage, as demonstrated by von Kossa
staining (Figure 2C).
Chondrogenic Dfferentiation
When spheroids of MSCs were cultured in
chondrogenic medium for 3 weeks, more than 80%-
90% of cells differentiated into cartilage cells, asFigure 2. In vitro differentiation and typical phenotypes of MSCs. (A) Cell mo
after adipogenic induction. (C) von Kossa staining of MSCs after osteogenic ind
Phenotypes of MSCs at the third passage.demonstrated by Safranin O staining for detecting
the synthesis of mucopolysaccharide (Figure 2D).
Immunomodulatory Effect on T Cell
Proliferation
To explore the mechanisms of MSCs in alleviating
ScGVHD, we examined the role of MSCs in T cell
proliferation. Irradiated MSCs were added to mito-
gen-stimulated T cells in a proliferation reaction.
MSCs clearly inhibited the T cell proliferation. In mi-
togen-sitmulated T cell proliferation, the proliferation
of T cells at a MSC: MNC ratio of 1:10 was signifi-
cantly inhibited, to about 80%. This result was
confirmed by subsequent experiments (Figure 3), sug-
gesting that MSCs may modulate the immune system
through inhibition of T cell proliferation.
Outcome of MSC Treatment for ScGVHD
The patients’ responses to MSC therapy and their
outcomes are summarized in Table 3. With a median
overall follow-up of 14.1 months (range, 4.6-23
months) from time of initiation of MSC therapy, all
4 patients exhibited improved RS score (.70%) and
decreased signs and symptoms. Patient 1 experienced
effective pain relief in the lower extremities on day
110 after the first MSC infusion. Skin sclerosis and
edema of the extremities were slightly alleviated; a yel-
low callus without exudates formed on the surface of
the foot ulcer. On day116, skin lesions (ie, desquama-
tion and edema of the extremities, and ulcers and exu-
dation on the right palm and both feet) were furtherrphology of MSCs at the third passage. (B) Oil Red O staining of MSCs
uction. (D) Safranin O staining of MSCs after chondrogenic induction. (E)
Figure 3. Effect of MSCs on T lymphocyte proliferation in mitogen
proliferative assays. Shown are nonstimulated T cells (T0), PHA-stimu-
lated T cells (Ts), and PHA-stimulated T cells cocultured with MSC at
a MSC:T cell ratio of 1:10. Data are given as the mean 6 standard
deviation of 3 independent experiments. *P\.05 versus T0; **P\.05
versus Ts.
408 Biol Blood Marrow Transplant 16:403-412, 2010H. Zhou et al.improved, with both hands dermatoglyph-visible. Fol-
lowing repeated intermittent MSC infusion, local skin
gradually became soft with the ability to be pinched,
and diffuse decrustation and newborn skin were
observed. Joint mobility increased, and pain in the
extremities vanished.
Patient 2 exhibited marked improvement in skin
condition after 4 rounds of MSC infusion. Skin sclero-
sis on the trunk and extremities was alleviated, and
joint mobility was greatly improved, allowing the
patient to walk without assistance. But, because the
patient suffered from psoriasis, her local skin (espe-
cially in the lower extremities and hands) remained
desquamative, with concomitant hyperpigmented
and hypopigmented lesions.
In patient 3, edema of the hands and feet was alle-
viated on day 16 after the first MSC infusion. On day
115, the patient reported local itching. By day 122,
desquamation decreased, and less desquamative skin
was produced. In addition, no ulcers or pyorrhea
were observed.
Patient 4 demonstrated the most striking improve-
ment. On day 114 after the initial MSC infusion, the
sclerotic and hyperpigmented skin in some areas
exhibited significantly improved elasticity and com-
plexion; the ulcer on the right ankle was healing,
with decreased exudate. By day 128, skin sclerosis
was further alleviated, the patient’s complexion was
shallowed noticeably, fine leg hairs were increased,Table 3. Outcome after MSC Therapy
Patient
MSC Therapy
Duration at Last
Follow-Up, Days Side Effects
RS Score before
MSC Therapy
1 52 None 28
2 47 None 24
3 22 None 21
4 52 None 35
MSC indicates mesenchymal stem cell; RS, Rodnan Skin.and the patient complained of intolerable itching of
the partial skin. On day 133, skin hairs were thicker,
and the patient complained of more frequent itching.
As immunity improved, the frequency of fever was
markedly reduced. After the 3 subsequent MSC infu-
sions, the patient’s condition improved; desquamation
and edema disappeared, skin elasticity recovered
somewhat, sweat gland and follicular orifice function
returned to normal, the ankle ulcer formed a scab
and healed, and joint mobility improved significantly
(Figure 4). In addition, MSC therapy allowed for
a significant tapering of standard medications (Tables
1 and 2).
Our findings indicate that MSCs begin to exert
their therapeutic effects during the first 2 weeks of
therapy, resulting in significant clinical improvement.
Furthermore, the efficacy of MSCs can be sustained
by repeated intermittent MSC infusion.Change in T Lymphocyte Subset after MSC
Infusion
To evaluate the change in the Th1 cell:Th2 cell ra-
tio before and after MSC infusion, PBMCs were
extracted and stimulated by polyclonal activators at
multiple times before and after MSC infusion. The
IFN-g–, IL-2–, IL-10–, and IL-4–producing cell pro-
portions were analyzed by flow cytometry. The results
show significantly higher proportions of IL-10– and
IL-4–producing cells compared with IL-2– and IFN-
g–producing cells, indicating an apparent imbalance
of the 2 T lymphocyte subsets. That is, Th0 cells expe-
rienced a differentiation imbalance and tended to be
Th2 cells before MSC treatment. Nevertheless, after
repeated intermittent MSC infusion, the proportions
of IL-10– and IL-4–producing cells gradually de-
creased, whereas the proportions of IL-2– and IFN-
g–producing cells gradually increased. This overall
trend was consistent in all 4 patients (Figure 5A-D).
The flow cytometry data were analyzed by statistical
methods to detect significant changes in the 4 patients
(Figure 5E and F). Specifically, the results indicate that
MSC infusion plays a role in down-regulating exces-
sive Th0-to-Th2 differentiation and increasing the
proportion of Th1 cells, thereby reversing the Th1
cell–Th2 cell imbalance and achieving a new equilib-
rium point in patients with ScGVHD.RS Score at
Last Follow-Up
Overall Follow-Up,
Months
Status at Last
Follow-Up
7 23 Alive
3 20.3 Alive
6 8.5 Alive
8 4.6 Alive
Figure 4. The change process of skin lesions before and after MSC infusion in patient 4. Shown are changes in the skin lesion of the neck (A), left arm
(B), back (C), and right ankle (D) on days 0,114,128,133,140,154,176,192, and1123 after initial MSC infusion. Over time, the skin became soft,
desquamation was reduced, skin color was shallowed, edema disappeared, and the ankle ulcer formed a scab and healed.
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The 4 patients involved in this trial were all closely
monitored for changes in body temperature, pulse,
respirations, blood pressure, oxyhemoglobin satura-
tion, and electrocardiography readings. Blood bio-
chemical examination of liver and kidney function
was conducted as well. No abnormalities were found.
In addition, with a median overall follow-up of 14.1
months (range, 4.6-23 months), none of the 4 patients
experienced a recurrence of leukemia. Overall, the
results suggest that MSC infusion is safe and reliable.DISCUSSION
Of the 3 major cell subsets, Th0 cells can differen-
tiate into Th1 or Th2 cells in response to certain
chemical signal stimuli, Th1 cells mostly secrete
IFN-g and IL-2, and Th2 cells mainly secrete IL-10
and IL-4. TheTh1 cell:Th2 ratio is considered amajor
factor reflecting immune status [24]. Th cell imbalance
is an important pathological mechanism that isreceiving increasing attention in the study of immune
system disorders; for example, an increase in Th1 cells
is reportedly associated with aGVHD, and an increase
in Th2 cells is an important factor in the development
of fibrosis [25,26]. Some studies have suggested that
cGVHD is an immunodeficient and autoimmune dis-
ease induced by an increasing proportion of Th2 cells
[1,2], and here we observed an increasing proportion of
Th2 cells in all 4 patients with ScGVHD, in accor-
dance with a previous report [27].
MSCs have an high proliferation capacity, multi-
lineage differentiation potential, and low immunoge-
necity. Previous investigations have shown that MSCs
may modulate the immune system through various
mechanisms (eg, inhibiting T cell proliferation
through direct contact and cytokine secretion).
Some studies also have found that MSCs can affect
the differentiation of Th cells, but this effect may
be inconsistent in normal and abnormal immune sys-
tems. In an earlier study, we found that in the pres-
ence of a physiological condition, MSCs mainly
inhibit Th0 cell differentiation to Th1 [28]. Similarly,
Figure 5. Percentage of intracellular cytokines producing T lymphocyte subsets detected by flow cytometry. (A) Patient 1: polygram detected by flow
cytometry on days 0,114,128, and149 of MSC infusion. (B) Patient 2: polygram detected by flow cytometry on days 0,114,139, and147 of MSC
infusion. (C) Patient 3: polygram detected by flow cytometry on days 0, 18, 115, and122 of MSC infusion. (D) Patient 4: polygram detected by flow
cytometry on days 0,17,114,128, and135 of MSC infusion. (E) Patient 4: histogram of IL-2–, IFN-g–, IL-10–, and IL4–producing T lymphocyte subsets
on days 0 and135 of MSC infusion. (F) Comparison of the 4 intracellular cytokines producing cells between before infusion of MSCs and the final infusion
of MSCs. The difference is statistically significant (*P\.05).
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Biol Blood Marrow Transplant 16:403-412, 2010 411MSCs Alleviate ScGVHDin increased Th1–related diseases like aGVHD, MSC
treatment also could reduce the proportion of Th1
cells, thereby improving the patient’s condition; this
effect has been confirmed in clinical applications
[17-20]. Nonetheless, the fact is that for some
increased Th2–related immune disorders, such as
acute-phase fibrosis, MSC transplantation also exerts
a good therapeutic effect [29,30]. Thus, MSC therapy
may be a therapeutic option for ScGVHD; clinical
trials are needed, however.
In normal BM, MSCs are very rare (1 out of 104-
105 MNCs). Thus, under normal conditions, MSCs
may not initiate the immune response to foreign an-
tigens, which is consistent with findings in vitro. In
both PHA-stimulated T cell proliferation reactions
and mixed lymphocyte reactions (MLRs), inhibition
of MSCs to T cell proliferation disappeared at an
MSC:MNC ratio of 1:100. Furthermore, MSCs’ im-
munomodulatory capacity in a normal immune sys-
tem in vivo is dose-dependent and disappears when
the number of infused MSCs drops to 104 [14].
But, MSCs can proliferate easily in vivo, and because
of low immunogenicity, MSCs can be transplanted
abundantly to treat immune system disorders. In ad-
dition, our previous study in animal models showed
that MSCs’ immunomodulatory capacity was intense
during the first 1-2 weeks after infusion, was obvi-
ously weakened after the third week, and almost dis-
appeared after the fourth week [28]. Because
ScGVHD is a chronic disease, we needed to repeat-
edly intermittently infuse MSCs, with the time inter-
val controlled at 1-2 weeks. Furthermore, in
accordance with our previous research [31,32], we
controlled the dose at an order of magnitude of
107. Gao et al. [33] reported that mouse MSCs given
intravenously were blocked in the lungs, and conse-
quently the homing of MSCs to BM was disturbed
[34]. Injecting MSCs directly into the BM might
markedly reduce their peripheral residence in the
lungs and liver, an advantage of this route; thus,
the 4 patients in this trial received their MSC infu-
sions through the anterosuperior iliac spine. After in-
termittently repeated MSC infusions, the ratio of Th
cells changed dramatically: Th1 increased and Th2
decreased, and a new Th cell balance was achieved.
Correspondingly, patient symptoms also gradually
improved, suggesting, an association between
ScGVHD and Th cell imbalance, which MSC can
reverse. Furthermore, after MSC therapy, all stan-
dard medications that the patients took could be ta-
pered significantly.
The 4 patients involved in this trial all underwent
NMA AHCT after the mitigation of primary leukemia
and subsequently developed cGVHD. Previous stud-
ies have shown that MSC transplantation can increase
the risk of leukemia recurrence [35]. Some studies have
claimed that AHCT recipients who develop GVHDexperience fewer leukemia recurrences and have a lon-
ger life span compared with those who do not develop
GVHD; these positive effects are achieved via the
graft-versus-leukemia (GVL) reaction [36]. GVHD
andGVL are usually concomitant; that is, the GVL ef-
fect is subdued when GVHD is attenuated, leading to
leukemia relapse. However, in this trial, from the be-
ginning of the MSC infusion to the end of the fol-
low-up period (median time, 14.1 months), none of
the 4 patients experienced recurrence of leukemia.
This suggests that the immunomodulatory effect of
MSCs is selective and controllable. In addition, no
MSC infusion–related adverse reactions or side effects
were observed, suggesting that MSC infusion is safe
and reliable.
To confirm the safety of isolated and cultured
MSCs in vitro for clinical applications, we designed
a preclinical Phase I trial to evaluate the feasibility
and security of intravenous infusion of these cells after
ex vivo expansion. Infusions of autologous MSCs cul-
tured in vitro at doses of 5  104/kg, 5  105/kg, and
2  106/kg were safe and well tolerated in healthy
volunteers [31].
In summary, despite its limited size, the present
study suggests a benefit of MSC infusion therapy in
treating ScGVHD. Further prospective investigations
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